6 research outputs found
Co-encapsulation of curcumin and doxorubicin in albumin nanoparticles blocks the adaptive treatment tolerance of cancer cells
n/
BM-MSCs alleviate diabetic nephropathy in male rats by regulating ER stress, oxidative stress, inflammation, and apoptotic pathways
Introduction: Diabetic nephropathy (DN), a chronic kidney disease, is a major cause of end-stage kidney disease worldwide. Mesenchymal stem cells (MSCs) have become a promising option to mitigate several diabetic complications.Methods: In this study, we evaluated the therapeutic potential of bone marrow-derived mesenchymal stem cells (BM-MSCs) in a rat model of STZ-induced DN. After the confirmation of diabetes, rats were treated with BM-MSCs and sacrificed at week 12 after treatment.Results: Our results showed that STZ-induced DN rats had extensive histopathological changes, significant upregulation in mRNA expression of renal apoptotic markers, ER stress markers, inflammatory markers, fibronectin, and intermediate filament proteins, and reduction of positive immunostaining of PCNA and elevated P53 in kidney tissue compared to the control group. BM-MSC therapy significantly improved renal histopathological changes, reduced renal apoptosis, ER stress, inflammation, and intermediate filament proteins, as well as increased positive immunostaining of PCNA and reduced P53 in renal tissue compared to the STZ-induced DN group.Conclusion: In conclusion, our study indicates that BM-MSCs may have therapeutic potential for the treatment of DN and provide important insights into their potential use as a novel therapeutic approach for DN
Pāgp Inhibition and Mitochondrial Impairment by Dual-Functional Nanostructure Based on Vitamin E Derivatives To Overcome Multidrug Resistance
Vitamin
E derivatives possess many essential features for drug-delivery applications,
such as biocompatibility, stability, improvement of water solubility
of hydrophobic compounds, anticancer activity, and the ability to
overcome multidrug resistance (MDR). Herein, vitamin E derivatives
are used to overcome MDR through a combined P-glycoprotein (P-gp)
inhibition and mitochondrial impairment strategy. A novel nanomicellar
drug-delivery system as a carrier for doxorubicin (DOX) was developed,
in which d-Ī±-tocopheryl polyethylene glycol 1000 succinate
was used as a P-gp inhibitor, Ī±-tocopheryl succinate was introduced
as a mitochondrial disrupting agent, and d-Ī±-tocopheryl
polyethylene glycol 2000 succinate was used as the main building block
of micelles. The optimal ratio between the components of the nanocarrier
was determined. The resultant DOX-loaded mixed micelles exhibited
a suitable size of 52.08 nm, high drug-loading encapsulation efficiency
(>98%), high stability, and pH-dependent drug release. In vitro
experiments demonstrated a significantly increased cytotoxic activity
of DOX-loaded mixed micelles against resistant MCF-7/Adr cells (45-fold
higher than DOX after 48 h of treatment). In vivo studies revealed
superior antitumor efficiency with less cardio- and hepatotoxicities
of DOX-loaded micelles compared with that of free DOX. These results
highlight that the developed DOX-loaded mixed micelles have a promising
potential to overcome MDR in chemotherapy for clinical usage
Near-Infrared Emission CuInS/ZnS Quantum Dots: All-in-One Theranostic Nanomedicines with Intrinsic Fluorescence/Photoacoustic Imaging for Tumor Phototherapy
Many theranostic
nanomedicines (NMs) have been fabricated by packaging
imaging and therapeutic moieties together. However, concerns about
their potential architecture instability and pharmacokinetic complexity
remain major obstacles to their clinical translation. Herein, we demonstrated
the use of CuInS/ZnS quantum dots (ZCIS QDs) as āall-in-oneā
theranostic nanomedicines that possess intrinsic imaging and therapeutic
capabilities within a well-defined nanostructure. ZCIS QDs were exploited
for multispectral optical tomography (MSOT) imaging and synergistic
PTT/PDT therapy. Due to the intrinsic fluorescence/MSOT imaging ability
of the ZCIS QDs, their size-dependent distribution profiles were successfully
visualized at tumor sites <i>in vivo</i>. Our results showed
that the smaller nanomedicines (ZCIS NMs-25) have longer tumor retention
times, higher tumor uptake, and deeper tumor penetration than the
larger nanomedicines (ZCIS NMs-80). The ability of ZCIS QDs to mediate
photoinduced tumor ablation was also explored. Our results verified
that under a single 660 nm laser irradiation, the ZCIS NMs had simultaneous
inherent photothermal and photodynamic effects, resulting in high
therapy efficacy against tumors. In summary, the ZCIS QDs as āall-in-oneā
versatile nanomedicines allow high therapeutic efficacy as well as
noninvasively monitoring tumor site localization profiles by imaging
techniques and thus hold great potential as precision theranostic
nanomedicines